People

AuraVax Therapeutics, which is developing intranasal antiviral technology licensed from Massachusetts General Hospital and the University of Houston, has named former Merck executive Joseph C. Sullivan as the company’s first CEO. Sullivan was most recently Chief… Read more . . .

Inhaled drug developer Savara has announced the appointments of former Strongbridge Biopharma executives Scott Wilhoit as Executive VP, Global Commercial, and Rob Lutz as Chief Operating Officer. The company also said that it had promoted Dave Lowrance from… Read more . . .

PureIMS has appointed Frank Lambert as Executive Director Commercialization. Lambert, who was most recently Executive Director of Business Development for Early Development Services at ICON, will lead commercialization efforts for the company’s Cyclops pre-filled disposable… Read more . . .

TFF Pharmaceuticals, which is developing dry powder inhaled and nasal formulations based on its thin film freezing particle engineering technology, has announced the appointment of Zamaneh Mikhak as Chief Medical Officer. Mikhak was most recently… Read more . . .

Inhaled antiviral developer Pneumagen has announced the appointment of Adaptimmune Therapeutics founder James Noble as non-executive Chairman of the company’s board of directors. Noble also co-founded Immunocore and serves as Chairman of Sutura Therapeutics, Celleron,… Read more . . .

Copley Scientific has announced the appointments of Jamie Clayton as Managing Director and Matthew Fenn as Head of Business Development. Clayton joined powder characterization specialist Freeman Technology in 2008 and then served as Freeman’s Operations… Read more . . .

Aerami Therapeutics has announced that its current Chief Operating Officer Lisa Yañez will succeed Steve Thornton as CEO, effective January 1, 2023. Thornton will continue as a member of the Board of Directors. Prior to… Read more . . .

TFF Pharmaceuticals, which develops dry powder inhalation products based on its thin film freezing technology, has announced that Glenn Mattes will step down as CEO and that he will be succeeded on an interim basis… Read more . . .

InvisiShield Technologies, which is developing a human antibody nasal spray designed to prevent SARS-CoV-2 infection, has announced the appointment of Gladstone Institute of Virology and Immunology founding director Warner C. Greene as President and Chief… Read more . . .